A single gene in the shorebird species known as ruffs controls the levels of testosterone in males, and this in turn affects ...

Scientists at Brazil's National Center for Research in Energy and Materials (CNPEM) have discovered a biocatalyst called ...

BioMarin exceeded Q4 earnings expectations, raised 2025 guidance, and projected strong Voxzogo growth. Analysts increased price targets following the results.

It is a unique member of the plastic family as it can be broken down into its constituent units (or monomers) by PETases, which are enzymes that degrade PET. Until now, scientists have discovered ...

The National Center for Research in Energy and Materials has filed a patent application for the enzyme, which is now being ...

At dsm-firmenich, the feed enzymes business is currently part of the Animal Nutrition & Health business unit, which itself ...

A virus originally found in animals, mpox – which causes the disease of the same name – is now circulating in humans. Since ...

Q4 2024 Earnings Call Transcript February 19, 2025 BioMarin Pharmaceutical Inc. beats earnings expectations. Reported EPS is $0.64, expectations were $0.54. Operator: Ladies and gentlemen, thank you ...

Adjusted EPS of $0.92 topped estimates of $0.53. Revenue climbed to $747 million, beating the forecasted $712 million. Net ...

The R&D head is looking for "clever science," which Friberg said is readily apparent in BioMarin’s recent research pact with CAMP4 Therapeutics. The partners are using CAMP4’s regulatory RNA platform ...

BioMarin Pharmaceutical (NASDAQ:BMRN – Get Free Report) had its price target boosted by equities researchers at Piper Sandler ...